Patents Assigned to Boehringer Ingelheim Vetmedica, Inc.
-
Publication number: 20090016992Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: ApplicationFiled: June 12, 2008Publication date: January 15, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20090010954Abstract: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.Type: ApplicationFiled: February 13, 2008Publication date: January 8, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Vicky Fachinger, Knut Elbers, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle Von Richthofen, Axel Lischewski
-
Publication number: 20080305128Abstract: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.Type: ApplicationFiled: January 3, 2008Publication date: December 11, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Vicky Fachinger, Knut Elbers, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle von Richthofen, Axel Lischewski
-
Publication number: 20080279889Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: November 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080279876Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: November 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080279875Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: November 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080267995Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: October 30, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080261887Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: October 23, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080260779Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: June 11, 2008Publication date: October 23, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080241190Abstract: The present invention is broadly concerned with vaccination of horses against proliferative enteritis, preferably equine proliferative ileitis, which is caused by an obligate intracellular bacterium Lawsonia Intracellularis (L. intracellularis). Specifically, the invention provides for a method of providing immune protection against L. intracellularis by vaccinating horses, preferably foals starting from one (1) week of age. Preferably the foals are vaccinated with about 4.9 log 10 to about 6.9 log 10 of a live modified L. intracellularis bacteria per dose.Type: ApplicationFiled: November 9, 2007Publication date: October 2, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Jeremy Kroll, Axel Neubauer, Philip Utley, Michael Roof, Juergen Daemmgen, Knut Elbers
-
Publication number: 20080226669Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: December 28, 2006Publication date: September 18, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Publication number: 20080193471Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.Type: ApplicationFiled: October 24, 2007Publication date: August 14, 2008Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Eric Vaughn, Paulino Carlos Gonzalez-Hernandez, Juergen Daemmgen
-
Publication number: 20080181910Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.Type: ApplicationFiled: December 28, 2006Publication date: July 31, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
-
Publication number: 20080112980Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.Type: ApplicationFiled: November 6, 2007Publication date: May 15, 2008Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B. Roof, Jeremy J. Kroll, Jeffrey P. Knittel
-
Publication number: 20080063648Abstract: The present invention provides a method of vaccinating a young animal against L. intracellularis infection comprising the step of administering to said animal an effective dose of L. intracellularis antigen. It also provides a method of vaccinating an animal, preferably a young animal, having anti-L.intracellularis antibodies or is exposed to anti-L.intracellularis antibodies. In particular, those anti-L.intracellularis antibodies are maternally derived antibodies.Type: ApplicationFiled: May 18, 2007Publication date: March 13, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventor: Jeremy Kroll
-
Patent number: 7312065Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.Type: GrantFiled: July 15, 2004Date of Patent: December 25, 2007Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Michael B. Roof, Jeremy J. Kroll, Jeffrey P. Knittel
-
Patent number: 7226604Abstract: A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.Type: GrantFiled: July 23, 2004Date of Patent: June 5, 2007Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventor: Mark W. Mellencamp
-
Patent number: 7081342Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: September 3, 2003Date of Patent: July 25, 2006Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
-
Patent number: 6982160Abstract: The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.Type: GrantFiled: May 6, 2004Date of Patent: January 3, 2006Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
-
Patent number: 6855315Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.Type: GrantFiled: October 28, 2002Date of Patent: February 15, 2005Assignees: Regents of the University of Minnesota, South Dakota State University, Boehringer Ingelheim Vetmedica, Inc.Inventors: James E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca